Key Events This Week
Mar 09: New 52-week low (Rs.306)
Mar 10: Intraday high surge (Rs.359.8)
Mar 10: Strong gap up opening (+7.72%)
Mar 13: Week closes at Rs.326.25 (+1.87%)
Mar 27
BSE+NSE Vol: 1.87 lacs

Panacea Biotec Ltd demonstrated robust intraday performance on 18 Mar 2026, surging 7.92% to touch a day’s high of Rs 340.95. This sharp uptick outpaced the broader Sensex, which gained 0.81%, and the Pharmaceuticals & Biotechnology sector, with Panacea Biotec outperforming its sector by 6.76% during the trading session.
Read full news article
Panacea Biotec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Mar 09: New 52-week low (Rs.306)
Mar 10: Intraday high surge (Rs.359.8)
Mar 10: Strong gap up opening (+7.72%)
Mar 13: Week closes at Rs.326.25 (+1.87%)

Panacea Biotec Ltd recorded a robust intraday performance on 10 Mar 2026, surging to a day’s high of Rs 359.8, marking a 7.47% gain. The stock outpaced the broader market and its sector, reflecting notable trading momentum amid a mixed market backdrop.
Read full news article
Panacea Biotec Ltd commenced trading today with a significant gap up, opening 7.72% higher than its previous close, signalling a robust start amid positive market sentiment. The stock outperformed its sector and broader indices, continuing a short-term upward trajectory following two consecutive days of gains.
Read full news article
Panacea Biotec Ltd’s shares declined to a fresh 52-week low of Rs.306 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s financial performance and market valuation, as it continues to underperform relative to broader indices and sector peers.
Read full news article
Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Panacea Biotec Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a strong long-term performance relative to the Sensex, recent weekly and monthly technical parameters suggest increasing downside pressure on the stock, prompting a downgrade to a Strong Sell rating.
Read full news articlePanacea Biotec Limited has informed the Exchange regarding 'Compliance under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding publication of Extract of Statement of Unaudited Financial Results for the quarter and half year ended 30.09.2019'.
Panacea Biotec Limited has informed the Exchange regarding Board meeting held on November 14, 2019.
Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during October, 2019 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018'.
No Upcoming Board Meetings
Panacea Biotec Ltd has declared 75% dividend, ex-date: 19 Sep 11
No Splits history available
No Bonus history available
No Rights history available